ScreenerHero

PBYIPuma Biotechnology, Inc.

NAS · US · Healthcare · Biotechnology · pumabiotechnology.com
9.240USD-2.63%Mkt Cap: 476.97M $P/E: 18.12

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of n…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap476.97M $
Enterprise Value381.17M $
Revenue (TTM)231.24M $
Gross Profit170.21M $
Net Income (TTM)31.11M $
Revenue/Share4.567 USD
Last Price9.240 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees179
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)18.12
P/E (Forward)26.03
PEG—
EV/EBITDA9.50
EV/Revenue1.65
P/S2.03
P/B3.36
EPS (TTM)0.49
EPS (Forward)0.35
52W Range
4.30095% of range9.510
52W High9.510 USD
52W Low4.300 USD
Profitability
Gross Margin74.53%
Oper. Margin13.42%
EBITDA Margin17.35%
Profit Margin13.62%
ROE23.87%
ROA14.38%
Growth
Revenue Growth7.80%
Earnings Growth35.80%
Cash Flow & Leverage
Operating CF41.80M $
CapEx (TTM)71.00K $
FCF Margin14.04%
FCF Yield6.81%
Net Debt-89.09M $
Net Debt/EBITDA-2.22
Balance Sheet
Debt/Equity0.22
Current Ratio2.91
Quick Ratio2.57
Book Value/Sh2.711 USD
Cash/Share1.819 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.000 USD
Upside (mean)-35.1%
Target Range6.000 USD – 6.000 USD
# Analysts1
Ownership
Shares Out.51.62M
Float39.62M
Insiders15.28%
Institutions75.58%
Short Interest
Short Ratio12.2d
Short % Float9.47%
Short % Out.8.07%
Shares Short4.13M
Short (prev mo.)3.63M
Technical
SMA 508.118 (+13.8%)
SMA 2006.830 (+35.3%)
Beta1.22
S&P 52W Chg18.16%
Avg Vol (30d)318.86K
Avg Vol (10d)339.27K
Technical Indicators
RSI (14)64.9
MACD0.3208
MACD Signal0.2246
MACD Hist.+0.0962
BB Upper9.472 USD
BB Middle8.377 USD
BB Lower7.282 USD
BB Width26.14%
ATR (14)0.4216 USD
Vol Ratio (20d)1.09x